Liraglutide significantly reduced autoimmune myocarditis severity in mice by suppressing NLRP3 inflammasome and NF-κB inflammatory pathways, improving heart function and reducing immune cell infiltration and fibrosis.
NLRP3 and NF-κB pathways suppressedRNA sequencing confirmed liraglutide modulates two key inflammatory pathways in autoimmune myocarditis, resulting in improved cardiac function and reduced immune cell infiltration
What the researchers found
Liraglutide significantly reduced myocarditis severity, as shown by lower heart weight/body weight ratio, reduced serum cardiac troponin T, decreased cardiac fibrosis, and diminished inflammatory infiltration. Echocardiography confirmed improved left ventricular function. Immunofluorescence and RT-qPCR showed decreased T-cell and macrophage infiltration with reduced pro-inflammatory cytokine expression. RNA sequencing identified the NLRP3 inflammasome and NF-κB pathways as the key targets modulated by liraglutide.
Why it matters
Myocarditis has gained increased attention since it was identified as a rare side effect of both COVID-19 infection and mRNA vaccines. Current treatments are limited to immunosuppressants with significant side effects. Finding that an already-approved, well-tolerated drug like liraglutide can reduce heart inflammation through specific pathways could quickly translate to clinical trials. The NLRP3/NF-κB mechanism also connects to the broader understanding of GLP-1RA anti-inflammatory effects seen across multiple organ systems.
How the study worked
Preclinical study using a mouse model of autoimmune myocarditis treated with liraglutide. Assessment included heart weight/body weight ratio, serum troponin T, echocardiography for cardiac function, histological staining for fibrosis and inflammation, immunofluorescence for immune cell infiltration, RT-qPCR for cytokine expression, and RNA sequencing for pathway analysis.
What this study cannot tell us
This is a mouse study using an induced autoimmune myocarditis model, which may not fully represent human myocarditis (often viral or idiopathic). Specific animal numbers, liraglutide doses, and treatment duration were not detailed in the abstract. The RNA sequencing identified pathways but direct causation (e.g., through specific inhibitors) was not confirmed. Human myocarditis has varied causes and presentations that a single mouse model cannot capture.
How to read the evidence
This is a preclinical mouse study with comprehensive characterization including echocardiography, histology, immunofluorescence, RT-qPCR, and RNA sequencing. While the mechanistic evidence is thorough, translation to human myocarditis requires clinical validation.
When this study was published
Published in 2025 in Scientific Reports (Nature portfolio), this study is timely given heightened awareness of myocarditis from COVID-19 and vaccine-related cases, and the ongoing expansion of GLP-1RA therapeutic applications.
The bigger picture
This study adds myocarditis to the growing list of inflammatory conditions where GLP-1 receptor agonists show therapeutic potential — joining neuroinflammation, atherosclerosis, kidney disease, and liver inflammation. The consistent finding that GLP-1RAs suppress the NLRP3 inflammasome across different tissues and disease models suggests this is a fundamental pharmacological effect of the drug class, not tissue-specific. As clinical trials explore GLP-1RAs for Alzheimer's and other inflammatory conditions, the cardiac anti-inflammatory data strengthens the case for broad anti-inflammatory applications.
Questions still open
- Would liraglutide be effective in viral myocarditis or immune checkpoint inhibitor-induced myocarditis, which have different mechanisms?
- Could GLP-1RAs prevent myocarditis in high-risk settings (e.g., post-COVID or during immune checkpoint therapy)?
- Is the NLRP3/NF-κB suppression mechanism shared by all GLP-1RAs or specific to liraglutide?
Common questions
What is myocarditis and why is it dangerous?
How does liraglutide reduce heart inflammation?
Read the original research
Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-κb pathways.
Scientific reports, 15(1), 27274
Citation
Zhang, Lijuan; Han, Lishuai; Lu, Yang; Chen, Quanzhou. (2025). Liraglutide attenuates autoimmune myocarditis by inhibiting NLRP3 and NF-κb pathways.. Scientific reports, 15(1), 27274. https://doi.org/10.1038/s41598-025-12715-y